Cargando…

Keloid treatment: what about adjuvant radiotherapy?

Background: Keloids are debilitating fibrous skin proliferations with a high recurrence rate after surgical treatment. Postoperative radiotherapy (PORT) is a well-tolerated adjuvant treatment to reduce the risk of recurrence, but the optimal regimen for this combined treatment remains unknown. The a...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrou, Ilias G, Jugun, Kheeldass, Rüegg, Eva Meia, Zilli, Thomas, Modarressi, Ali, Pittet-Cuénod, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526192/
https://www.ncbi.nlm.nih.gov/pubmed/31190938
http://dx.doi.org/10.2147/CCID.S202884
_version_ 1783419851347329024
author Petrou, Ilias G
Jugun, Kheeldass
Rüegg, Eva Meia
Zilli, Thomas
Modarressi, Ali
Pittet-Cuénod, Brigitte
author_facet Petrou, Ilias G
Jugun, Kheeldass
Rüegg, Eva Meia
Zilli, Thomas
Modarressi, Ali
Pittet-Cuénod, Brigitte
author_sort Petrou, Ilias G
collection PubMed
description Background: Keloids are debilitating fibrous skin proliferations with a high recurrence rate after surgical treatment. Postoperative radiotherapy (PORT) is a well-tolerated adjuvant treatment to reduce the risk of recurrence, but the optimal regimen for this combined treatment remains unknown. The aim of this study is to evaluate the efficacy of combining surgical excision and immediate PORT. Methods: We retrospectively reviewed the records of patients with keloid lesions treated with adjuvant PORT in the period 2005–2014 at Geneva University Hospitals. Main outcomes were the rates of complications and recurrence in patients with a minimal follow-up of 1 year, including the Patient and Observer Scar Assessment Scale satisfaction scores. Results: 10 patients with 16 keloids were eligible (mean follow-up, 37 months). Only one recurrence was reported (6%). In 12.5% of cases, mild erythema appeared in the early postoperative period. No major complications were observed. The overall patient and observer satisfaction rate was excellent. Conclusion: Surgical excision combined with immediate PORT is an effective and easy treatment with good esthetic results and an acceptable recurrence rate. It should be considered for patients with persistent keloid formation after failure of other treatments and those at high risk of relapse.
format Online
Article
Text
id pubmed-6526192
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65261922019-06-12 Keloid treatment: what about adjuvant radiotherapy? Petrou, Ilias G Jugun, Kheeldass Rüegg, Eva Meia Zilli, Thomas Modarressi, Ali Pittet-Cuénod, Brigitte Clin Cosmet Investig Dermatol Original Research Background: Keloids are debilitating fibrous skin proliferations with a high recurrence rate after surgical treatment. Postoperative radiotherapy (PORT) is a well-tolerated adjuvant treatment to reduce the risk of recurrence, but the optimal regimen for this combined treatment remains unknown. The aim of this study is to evaluate the efficacy of combining surgical excision and immediate PORT. Methods: We retrospectively reviewed the records of patients with keloid lesions treated with adjuvant PORT in the period 2005–2014 at Geneva University Hospitals. Main outcomes were the rates of complications and recurrence in patients with a minimal follow-up of 1 year, including the Patient and Observer Scar Assessment Scale satisfaction scores. Results: 10 patients with 16 keloids were eligible (mean follow-up, 37 months). Only one recurrence was reported (6%). In 12.5% of cases, mild erythema appeared in the early postoperative period. No major complications were observed. The overall patient and observer satisfaction rate was excellent. Conclusion: Surgical excision combined with immediate PORT is an effective and easy treatment with good esthetic results and an acceptable recurrence rate. It should be considered for patients with persistent keloid formation after failure of other treatments and those at high risk of relapse. Dove 2019-05-03 /pmc/articles/PMC6526192/ /pubmed/31190938 http://dx.doi.org/10.2147/CCID.S202884 Text en © 2019 Petrou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Petrou, Ilias G
Jugun, Kheeldass
Rüegg, Eva Meia
Zilli, Thomas
Modarressi, Ali
Pittet-Cuénod, Brigitte
Keloid treatment: what about adjuvant radiotherapy?
title Keloid treatment: what about adjuvant radiotherapy?
title_full Keloid treatment: what about adjuvant radiotherapy?
title_fullStr Keloid treatment: what about adjuvant radiotherapy?
title_full_unstemmed Keloid treatment: what about adjuvant radiotherapy?
title_short Keloid treatment: what about adjuvant radiotherapy?
title_sort keloid treatment: what about adjuvant radiotherapy?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526192/
https://www.ncbi.nlm.nih.gov/pubmed/31190938
http://dx.doi.org/10.2147/CCID.S202884
work_keys_str_mv AT petrouiliasg keloidtreatmentwhataboutadjuvantradiotherapy
AT jugunkheeldass keloidtreatmentwhataboutadjuvantradiotherapy
AT rueggevameia keloidtreatmentwhataboutadjuvantradiotherapy
AT zillithomas keloidtreatmentwhataboutadjuvantradiotherapy
AT modarressiali keloidtreatmentwhataboutadjuvantradiotherapy
AT pittetcuenodbrigitte keloidtreatmentwhataboutadjuvantradiotherapy